Regeneus (ASX:RGS) Patent Granted For Protecting Cryopreserved Stem Cells
Sydney, Dec 19, 2014 - (ABN Newswire) - Regenerative medicine company, Regeneus Ltd (ASX:RGS), announced today the granting by the Australian Patent Office of Australian patent number 2013203072. This Regeneus owned patent covers a method for freezing cells that maintains viability and functionality of the cells. The method utilizes Regeneus' secretions technology to protect the cells during the freeze and thawing process.
Regeneus' secretions technology uses the molecules (including cytokines and growth factors) that are secreted by mesenchymal stem cells (MSCs). Regeneus has developed technology and protocols for the production of secretions from adipose (fat)-derived MSCs and has discovered that when cells are mixed with these secretions prior to freezing the viability and functionality of the cells is maintained. This te chnology is applicable to many different cell types.
Regeneus CSO, Professor Graham Vesey said, "Off-the-shelf cell therapy products need to be stored and delivered to the patient in a frozen state. The viability, functionality and subsequent efficacy of these frozen and then thawed cells are critical for maximizing therapeutic value. When cells are frozen, damage can occur that causes the cells to lose their ability to function correctly. The cells may still be alive but are too damaged to have a therapeutic effect. Our research shows that when cells are mixed with secretions from MSCs prior to being frozen the cells maintain their functionality. Regeneus is using this technology in a number of our off-the- shelf cell therapy products".
A recent news story from the BBC highlights the issues with the loss of cell function after freezing cells.
To view the BBC Story, please visit:
http://w ww.bbc.com/news/health-30194504
This is the second Regeneus patent to be granted in Australia and follows on from the announcement of a Regeneus patent being granted on the 14th November for the treatment of acne. Regeneus has 11 patent families covering their technology and products, which are at various stages of the patent review process. The company anticipates further patents being granted this financial year.
WEB: Patent granted for protecting cryopreserved stem cells
About: Regeneus Ltd
Regeneus Ltd (ASX:RGS) is a Sydney-based ASX listed regenerative medicine company that develops and commercialises stem cell and other biological therapies for the human and veterinary health markets with a focus on musculoskeletal and oncology conditions. The company has a marketed autologous (patient's cells) product using adipose (fat) derived stem cells to treat human osteoarthritis (OA), HiQCell, which has been used to treat over 1000 arthritic joints. The company plans to commence a clinical trial of allogeneic (donor cells) adipose stem cells to treat human OA in Q2 2015.
Contact:
Sandra McIntosh
Company Secretary
Regeneus Ltd
T: +61 2 9499 8010
E: investors@regeneus.com.au
W: www.regeneus.com.au
Help employers find you! Check out all the jobs and post your resume.
Regeneus' secretions technology uses the molecules (including cytokines and growth factors) that are secreted by mesenchymal stem cells (MSCs). Regeneus has developed technology and protocols for the production of secretions from adipose (fat)-derived MSCs and has discovered that when cells are mixed with these secretions prior to freezing the viability and functionality of the cells is maintained. This te chnology is applicable to many different cell types.
Regeneus CSO, Professor Graham Vesey said, "Off-the-shelf cell therapy products need to be stored and delivered to the patient in a frozen state. The viability, functionality and subsequent efficacy of these frozen and then thawed cells are critical for maximizing therapeutic value. When cells are frozen, damage can occur that causes the cells to lose their ability to function correctly. The cells may still be alive but are too damaged to have a therapeutic effect. Our research shows that when cells are mixed with secretions from MSCs prior to being frozen the cells maintain their functionality. Regeneus is using this technology in a number of our off-the- shelf cell therapy products".
A recent news story from the BBC highlights the issues with the loss of cell function after freezing cells.
To view the BBC Story, please visit:
http://w ww.bbc.com/news/health-30194504
This is the second Regeneus patent to be granted in Australia and follows on from the announcement of a Regeneus patent being granted on the 14th November for the treatment of acne. Regeneus has 11 patent families covering their technology and products, which are at various stages of the patent review process. The company anticipates further patents being granted this financial year.
WEB: Patent granted for protecting cryopreserved stem cells
About: Regeneus Ltd
Regeneus Ltd (ASX:RGS) is a Sydney-based ASX listed regenerative medicine company that develops and commercialises stem cell and other biological therapies for the human and veterinary health markets with a focus on musculoskeletal and oncology conditions. The company has a marketed autologous (patient's cells) product using adipose (fat) derived stem cells to treat human osteoarthritis (OA), HiQCell, which has been used to treat over 1000 arthritic joints. The company plans to commence a clinical trial of allogeneic (donor cells) adipose stem cells to treat human OA in Q2 2015.
Contact:
Sandra McIntosh
Company Secretary
Regeneus Ltd
T: +61 2 9499 8010
E: investors@regeneus.com.au
W: www.regeneus.com.au
Help employers find you! Check out all the jobs and post your resume.